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Increased relaxin (RLN) peptide expression has been found in prostrate, breast, and 
endometrial cancers. The proliferative and anti-apoptotic effects of relaxin contribute to 
cancer growth, and thus a small-molecule antagonist of relaxin signaling may inhibit these 
cancer-promoting effects. We have identified several antagonists, which suppress 
activation of the G protein-coupled relaxin receptor, relaxin/insulin like family peptide 
receptor 1 (RXFP1), and are completely or partially ineffective against the closely related 
receptor RXFP2. The goal of this study is to define the region of relaxin receptor 
responsible for antagonist response. Comparison of amino acid sequences between RXFP1 
and RXFP2 revealed 14 differences in this region of the proteins from which we created 
point mutants to analyze the differential response of the two receptors. The activation of 
the receptors transiently transfected in HEK293T cells was quantified by measuring cyclic 
AMP (cAMP) production, which is induced when RXFP1 is stimulated by RLN or when 
RXFP2 is activated by its cognate ligand, INSL3. It was determined that a singular amino 
acid change in RXFP1 is not sufficient to affect antagonistic response. Then, we tested the 
efficacy of the antagonists against a series of mutant receptors containing different portions 
of RXFP1 and RXFP2. The cDNA fragments of the two receptors were produced using 
high-fidelity PCR and combined by an infusion protocol. All chimeric receptors were 
tested for their cAMP response to RLN and INSL3. First, two chimeric receptors were 
analyzed: RXFP1/2 and RXFP2/1, containing the ectodomain of one receptor and seven 
transmembrane domain (7TM) of the second. An additional 5 chimeras were created with 
the C-terminal parts of the RXFP1 or RXFP2 7TM. The substitution of the 7TM in RXFP2 
with the RXFP1 domain rendered the chimeric receptor more responsive to antagonists. 
Furthermore, another two chimeras were created to assess the significance of the individual 
C-terminal parts for RXFP1 and RXFP2 on overall antagonism. Our data provides insight 
on the nature of small molecule binding to the receptor, which will facilitate further 
modifications of the antagonists to increase their activity and efficacy as a potential agent 
to suppress tumorigenesis.  
 
